Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Faces New ICER Roadblock To Repatha Reimbursement

Executive Summary

The Institute for Clinical and Economic Review is lowering the value-based pricing benchmark for Amgen's PCSK9 inhibitor based on the results of the FOURIER cardiovascular outcomes trial – which was positive overall but did not show a reduction in CV mortality.

Advertisement

Related Content

PCSK9 Sales Still Slow, But May Get Boost From Label, Guideline Changes
Amgen's Ofman On Value-Based Contracts And Reimbursement Challenges
PCSK9 Sponsors Still Face Challenges In Turning Around Dismal Launches
Amgen's Repatha Contract With Harvard Pilgrim Includes A Full Refund
PCSK9 Revised Analysis Indicates Less Price Discounting May Be Needed

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098955

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel